Navigation Links
SEQUENOM Reports Second Quarter 2009 Financial Results and Highlights
Date:8/6/2009

Securities

As of June 30, 2009, SEQUENOM had total cash, cash equivalents and short- and long-term marketable securities of $69.3 million and $7.5 million in accounts receivable.

"This recent period has been a challenging time for SEQUENOM. Our announcement at the end of April was immensely disappointing and has resulted in a setback in our molecular diagnostics programs. However, I believe we are at a point where we can look forward to other promising developments for SEQUENOM," said Harry Stylli, PhD, president and CEO of SEQUENOM. "We have made improvements to our MassARRAY platform and we are poised to introduce a series of molecular diagnostics tests to the market, including the first of those based on cell free fetal nucleic acids."

2009 Second Quarter and Recent Highlights

Genetic Analysis

Compact 96 Launch - With the launch of the Compact 96 system the company continues to make improvements to its MassARRAY platform. This next generation MassARRAY system addresses the needs of lower throughput laboratories. The combination of the features of the new MassARRAY Compact 96 system - accuracy, sensitivity, and now the ability to cost-effectively run fewer samples, make this new offering an ideal system for use in clinical laboratories.

OncoCarta Panel - The company continues to benefit from market acceptance of the OncoCarta panel. OncoCarta is a comprehensive multi-gene panel available for profiling rare somatic mutations. It enables researchers to rapidly profile genetic changes associated with tumor initiation and progression. The company expects to add more oncogenes and mutations to the OncoCarta panel in the near future.

Diagnostics Business

Commercial Launch Plans - The company is on track to launch three diagnostic products through its CLIA laboratory by the first quar
'/>"/>

SOURCE SEQUENOM, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. SEQUENOM Announces Launch of MassARRAY Compact 96 System
2. SEQUENOM to Hold First Quarter 2009 Financial Results Conference Call on April 30
3. Webcast Alert: Sequenom: Defining the Future of Noninvasive Prenatal Diagnostics
4. Sequenom to Webcast Analyst and Investor Briefing Presentation on June 3
5. Sequenom to Webcast Analyst and Investor Briefing Presentation on September 24
6. OncoGenex Reports Second Quarter 2009 Financial Results
7. Repligen Reports First Quarter Fiscal Year 2010 Financial Results
8. PDI Reports 2009 Second Quarter Financial Results
9. Cadence Pharmaceuticals Reports Second Quarter 2009 Financial Results
10. Optimer Pharmaceuticals Reports Second Quarter 2009 Financial Results
11. NxStage Reports Second Quarter 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... MILWAUKEE, Wis. (PRWEB) , ... July 29, 2015 ... ... facility identification solutions, today announced its GHS Label Guide . To align ... Harmonized System (GHS), this guide includes explanations of label components, an example of ...
(Date:7/29/2015)...  Therapath Neuropathology ( www.Therapath.com ), a leader ... and Military Medical centers both domestically and worldwide.  ... Sweat Gland Nerve Fiber Density (SGNFD) for the ... Demonstration of a reduction in ... skin biopsy is a highly sensitive and specific ...
(Date:7/29/2015)... -- Indivior PLC (LON: INDV) today announced that the New ... and received Priority Review by the U.S. Food and ... This naloxone nasal spray comes as a pre-filled device ... the nasal mucosa. 1 The device has been ... better equipped to help an opioid overdose victim. ...
(Date:7/29/2015)... - RepliCel Life Sciences Inc. (OTCQB: REPCF) (TSX.V: RP), ... announce that the final design specifications of its ... for industrial and regulatory testing will now be ... mark clearance to market the injector in ... (Photo: http://photos.prnewswire.com/prnh/20150729/248373 )  The RCI-02 ...
Breaking Biology Technology:Brady Announces a New GHS Label Guide 2Neuropathology services for VA and Military health systems 2Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 2Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 3Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 4Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 5RepliCel Life Sciences Unveils Innovative Dermal Injector Prototype 2RepliCel Life Sciences Unveils Innovative Dermal Injector Prototype 3RepliCel Life Sciences Unveils Innovative Dermal Injector Prototype 4RepliCel Life Sciences Unveils Innovative Dermal Injector Prototype 5
... MOUNTAIN VIEW, Calif., May 12 Alexza,Pharmaceuticals, Inc. (Nasdaq: ... quarter ended March 31, 2008 and provided an update ... loss for the 2008,first fiscal quarter, as reported in ... (GAAP), was $14.6 million, compared,to a net loss of ...
... IDIX ) announced today that Idenix management,will present ... Annual Global,Healthcare Conference on Tuesday, May 20, 2008 at ... Monte Carlo, Monaco., The live and archived webcast ... Events" in the Idenix Investor Center at, http://www.idenix.com . ...
... N.J., May 12 Synvista Therapeutics,Inc. (Amex: SYI ) ... Officer of Synvista will present at the upcoming Rodman,& Renshaw ... 12:10 p.m. CEST (6:10 a.m. EDT). The event will be ... Hotel in Monte Carlo., Dr. Berkowitz will discuss the ...
Cached Biology Technology:Alexza Reports 2008 First Quarter Financial Results and Updates Development of Product Candidates 2Alexza Reports 2008 First Quarter Financial Results and Updates Development of Product Candidates 3Alexza Reports 2008 First Quarter Financial Results and Updates Development of Product Candidates 4Alexza Reports 2008 First Quarter Financial Results and Updates Development of Product Candidates 5Alexza Reports 2008 First Quarter Financial Results and Updates Development of Product Candidates 6Alexza Reports 2008 First Quarter Financial Results and Updates Development of Product Candidates 7Alexza Reports 2008 First Quarter Financial Results and Updates Development of Product Candidates 8Alexza Reports 2008 First Quarter Financial Results and Updates Development of Product Candidates 9Alexza Reports 2008 First Quarter Financial Results and Updates Development of Product Candidates 10Synvista Therapeutics to Present at Acumen BioFin Rodman & Renshaw 5th Annual Global Healthcare Conference 2Synvista Therapeutics to Present at Acumen BioFin Rodman & Renshaw 5th Annual Global Healthcare Conference 3
(Date:7/8/2015)... 8, 2015  Trovagene, Inc. (NASDAQ: TROV ... announced the launch of a study that aims ... Monitoring℠ (PCM) technology for predicting response to treatment ... combination of the novel immunotherapy agents Yervoy® (ipilumumab), ... inhibitor. The 50-patient study will be led by ...
(Date:7/2/2015)... 2015 Research and ... the "Natural Language Processing Market by Type ... Pattern & Image Recognition) - Worldwide Forecast to ... The key vendors occupying the market are 3M, ... Corporation, NetBase Solutions, SAS Institute Inc., Verint Systems ...
(Date:6/29/2015)... Research and Markets( http://www.researchandmarkets.com/research/zj7h4f/latin_america ... America Biomedical Sensors Market - Growth, Trends & Forecasts ... Latin America Biomedical Sensors market is estimated at $0.65 ... the period 2014-2020 The near future will ... formulation of each individual. These sensors can be set ...
Breaking Biology News(10 mins):Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 4Natural Language Processing Market by Type (Rule-Based, Statistical, and Hybrid), Technologies (Recognition, IVR, OCR, Pattern & Image Recognition) - Worldwide Forecast to 2020 2Latin America Biomedical Sensors Market Report 2015-2020 2
... 2009 A canine chromosome 7 locus that confers ... identified through a collaboration between the Behavior Service at ... Medical Genetics at the University of Massachusetts Medical School ... Technology. The findings are published in the January 2010 ...
... lll. Researchers report that Helicobacter pylori , ... environment of the human stomach, directly activates an enzyme ... types of cancer, including gastric cancer. Chronic infection ... factor for several forms of gastric cancer, but researchers ...
... scientific conference has provided new evidence for the ... of spectacular marine life, including deadly jellyfish, basking ... ,South West Marine Ecosystems, meeting, held in Plymouth ... the scientific, conservation, fishing and eco-tourism sectors. The ...
Cached Biology News:Canine compulsive disorder gene identified in dogs 2Canine compulsive disorder gene identified in dogs 3Team finds link between stomach-cancer bug and cancer-promoting factor 2Team finds link between stomach-cancer bug and cancer-promoting factor 3Conference highlights impact of unsettled summer weather on UK marine life 2
... enzyme mix (Thermoprime Plus DNA Polymerase with ... four times higher fidelity than standard Taq ... Taq DNA polymerase, Amplifies DNA templates >20kb, ... PCR, PCR for cloning and mutagenesis We ...
RNA oligomers from 10 to 50 bases purified by PAGE and MS-checked. RNAs are supplied dried and fully deprotected....
... Incubator/Shaker HT is designed for ... Incubator/Shaker HT is ideal for ... and primer extension assays. The ... as a one-cabinet model, allowing ...
... is a modified cap analog in which ... is replaced with OCH3. Because of this ... transcription with the remaining hydroxyl group thus ... As a result, unlike transcripts synthesized with ...
Biology Products: